In a phase III noninferiority trial (NRG Oncology RTOG 0415) reported by Lee et al in the Journal of Clinical Oncology, W. Robert Lee, MD, MS, Med, of Duke University Medical Center, and colleagues found that hypofractionated radiotherapy was not inferior to conventional hypofractionated...
Hypofractionated radiotherapy was not inferior to conventional radiotherapy in terms of disease-free survival among men with low-risk prostate cancer, according to the results of the phase III NRG Oncology RTOG 0415 trial reported in the Journal of Clinical Oncology by Lee et al. However, it was...
W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).
Hypofractionated radiation therapy results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research (Abstract LBA6) presented by Lee et al October 19, 2015, at the American Society for Radiation Oncology...
New research from The Cancer Institute of New Jersey suggests that more stringent criteria may be needed for African American men with prostate cancer when considering active surveillance of the disease. The findings, published in the latest online version of Urology found that the prevalence ...